TRV
BPMC

Third Rock Ventures’s Blueprint Medicines BPMC Stock Holding History

Third Rock Ventures’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		$158M Hold
7,393,059
– – 14.73% 3
2015
Q2 		$196M Buy
+7,393,059
New +$211M 20.38% 2

Other funds holding BPMC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
RIM
RS Investment Management San Francisco, California $9.73B AUM 3.24% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Third Rock Ventures's BPMC Position: Q3 2015 in Review

Third Rock Ventures held its Blueprint Medicines (BPMC) position steady in Q3 2015 at 7,393,059 shares worth $158M. The position accounts for 14.73% of the portfolio, ranked #3.

Third Rock Ventures first reported a position in BPMC in Q2 2015 and has held it in 2 quarters since. The position peaked at $196M in Q2 2015. 70 funds tracked by Wall St. Rank hold BPMC as of Q3 2015.

  • Third Rock Ventures held 7,393,059 shares of Blueprint Medicines worth $158M as of Q3 2015.
  • Third Rock Ventures left its Blueprint Medicines share count unchanged in Q3 2015.
  • Blueprint Medicines made up 14.73% of Third Rock Ventures's portfolio in Q3 2015, its #3 holding.
  • Third Rock Ventures first reported a position in Blueprint Medicines in Q2 2015 and has held it in 2 quarters since.
  • Third Rock Ventures's Blueprint Medicines position peaked at $196M in Q2 2015.
  • 70 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2015.

Based on Third Rock Ventures's 13F filing for Q3 2015, filed 3 Nov 2015.